Pulsed focused ultrasound enhances the therapeutic effect of mesenchymal stromal cell-derived extracellular vesicles in acute kidney injury

Mujib Ullah, Daniel D. Liu, Sravanthi Rai, Mehdi Razavi, Waldo Concepcion and Avnesh S. Thakor*

Abstract

Background: Acute kidney injury (AKI) is characterized by rapid failure of renal function and has no curative therapies. Mesenchymal stromal cell (MSC)-derived extracellular vesicles (EVs) are known to carry therapeutic factors, which have shown promise in regenerative medicine applications, including AKI. However, there remains an unmet need to optimize their therapeutic effect. One potential avenue of optimization lies in pulsed focused ultrasound (pFUS), where tissues-of-interest are treated with sound waves. pFUS has been shown to enhance MSC therapy via increased cell homing, but its effects on cell-free EV therapy remain largely unexplored.

Methods: We combine pFUS pretreatment of the kidney with MSC-derived EV therapy in a mouse model of cisplatin-induced AKI.

Results: EVs significantly improved kidney function, reduced injury markers, mediated increased proliferation, and reduced inflammation and apoptosis. While pFUS did not enhance EV homing to the kidney, the combined treatment resulted in a superior therapeutic effect compared to either treatment alone. We identified several molecular mechanisms underlying this synergistic therapeutic effect, including upregulation of proliferative signaling (MAPK/ERK, PI3K/Akt) and regenerative pathways (eNOS, SIRT3), as well as suppression of inflammation.

Conclusion: Taken together, pFUS may be a strategy for enhancing the therapeutic efficacy of MSC-derived EV treatment for the treatment of AKI.

Keywords: Extracellular vesicles, Mesenchymal stromal cells, Acute kidney injury, Focused ultrasound, Regenerative medicine, Homing

Background

Acute kidney injury (AKI) is a condition characterized by a rapid deterioration of kidney function and is a common problem in hospitalized patients as well as those with comorbid chronic diseases [1]. In the past few decades, there has been a substantial increase in hospitalizations for AKI, with the Centers for Disease Control and Prevention (CDC) estimating the number of hospitalizations in the USA increasing over fourfold from 953,926 in 2000 to 3,959,560 in 2014 [2]. Studies in other countries have shown similar trends, with dialysis-treated AKI reportedly increasing more than thirteen-fold in England from 1998 to 2013 [3] and approximately threefold in Denmark from 2000 to 2012 [4]. AKI is especially prevalent among critically ill patients and is often secondary to another pathology. In addition to being an independent risk factor for end-stage renal disease (ESRD) and death [5], multiple
studies have shown that AKI may initiate the development of chronic kidney disease (CKD) or, where CKD is already present, accelerate its worsening [5–10]. Treatment for AKI is predominantly supportive, aimed at maintaining volume homeostasis and correcting biochemical abnormalities. Hence, there is an urgent need for new therapies that might actually repair injured kidneys and prevent the progression to worsening kidney disease.

Recently, there has been interest in the regenerative properties of mesenchymal stromal cell (MSC) therapy for the repair and regeneration of damaged kidney tissue [11, 12]. MSCs are a heterogeneous population of cells found in various adult tissues. Due to their immuno-modulatory and regenerative properties, as well as their ease of isolation and in vitro expansion, MSCs have been extensively explored as a platform for cellular therapy [13]. Early animal studies have shown that MSCs are capable of homing to damaged kidney tissue and contributing to renal repair [14, 15]. Recently, it has become clear that the therapeutic effects of MSCs come not from their ability to directly differentiate into new cells, but rather by the release of soluble factors and extracellular vesicles (EVs) with regenerative properties [16]. These molecules act through paracrine signaling to stimulate repair via anti-inflammatory, mitogenic, vasculotrophic, and pro-survival pathways, which provide protection for surviving intrinsic epithelial cells and promote their proliferation [17, 18]. Since MSCs act via paracrine signaling, their proximity to the injured site is believed to be crucial for tissue regeneration. However, multiple studies have shown that when MSCs are injected intravenously, they are predominantly trapped in the lung microvasculature, in what is termed the pulmonary first-pass effect [19–23]. Consequently, instead of using whole cells, many studies have now begun investigating the use of purified EVs from MSC as a cell-free therapy [24], which are small enough to avoid pulmonary trapping [25]. MSC-derived EVs carry a cargo of regenerative molecules and have been shown to have a therapeutic effect in various animal models of disease [26, 27].

Despite the growing interest in EVs for regenerative applications, there remains an unmet need to improve their therapeutic effect. One promising avenue of optimization could be the use of pulsed focused ultrasound (pFUS) [28]. pFUS uses short-duration, high-intensity pulses of sound waves to non-destructively sonicate target tissues. When combined with imaging guidance, pFUS can be targeted precisely to locations deep within the body. Previous studies have shown that pFUS can enhance MSC therapy for AKI [29, 30], but different mechanisms have been proposed for this effect. The homing hypothesis posits that sound waves transiently upregulate local inflammatory and chemotactic signals [31–33]. This local gradient of cytokines, chemokines, and trophic factors has been shown to promote the homing of MSCs to various tissues including the skeletal muscle [34, 35] and the kidney [29, 30, 32, 36]. In the setting of a mouse model of cisplatin-induced AKI, this increased homing of MSCs after pFUS was able to improve renal function more so than MSCs alone [30]. However, we have previously demonstrated that pFUS can enhance MSC therapy without local upregulation of cytokines or increased MSC homing [29]. Instead, pFUS was shown to act through protein intermediates to spur endogenous proliferation pathways, an effect which synergized with MSCs. These two mechanisms may not necessarily be at odds with one another, but may instead reflect differences in ultrasound parameters leading to differences in subsequent bioeffects [28]. Although there have been many studies on the effect of pFUS on MSC therapy, little is known about its effect on EV therapy. Hence, in this study, we use a mouse model of cisplatin-induced AKI to assess the effect of pFUS on MSC-derived EV therapy.

Methods

Extracellular vesicle isolation, characterization, and purification

Human bone marrow-derived MSCs (BM-MSCs) pooled from three donors were purchased from ATCC (PCS-500-012), transduced with GFP, and cultured in tissue culture flasks containing proliferative medium containing 10% fetal bovine serum (FBS), Dulbecco’s modified Eagle medium (DMEM), 100 μg/mL penicillin/streptomycin, and 2 mmol/mL glutamine (Thermo Fisher Scientific, USA) at 5% CO₂ until passage 4, with culture media change every 2 days. The BM-MSCs were then plated in a flask at 2 × 10⁴ cells/cm² with media containing DMEM, 100 μg/mL penicillin/streptomycin, 2 mmol/mL glutamine, and 3% EV-free FBS for the isolation of EVs. After overnight incubation, the conditioned media were centrifuged at 4°C at 300×g for 10 min to remove dead cells, 17,000×g for 10 min to remove cellular debris, and 110,000×g for 90 min to pellet EVs. EVs were washed with PBS and ultracentrifuged again before use. We then applied this medium at room temperature to a column containing the anion exchange resin (Q Sepharose Fast Flow, GE Healthcare, IL, USA) balanced with 50 mM NaCl in 50 mM phosphate buffer and washed with 100 mM NaCl in 50 mM phosphate buffer and then rinsed with 500 mM NaCl in 50 mM phosphate buffer. EV fractions (20–30 mL) were pooled, dialyzed against PBS, filter sterilized, and used for this study. Nanoparticle tracking analysis (NTA) was performed using NanoSight NS300 (ATA Scientific, Australia) for assessment of the size and number of the isolated EVs. NTA 3.3 Software was used for measurements and data output. The mean diameter was 118 nm and standard deviation 27 nm, with sizes ranging from 20 to 180 nm (Fig. 1a). EVs were characterized by expression of the following...
human protein markers: CD9, CD63, CD81, and TSG101, all of which were positive.

Animal experiments
All experimental procedures were performed in accordance with the guidelines and regulations of the Administrative Panel on Laboratory Animal Care (APLAC) at Stanford University. A total of 50 female CD1 mice (8 weeks old; body weight 30 ± 2 g) were purchased from Charles River Laboratories (Wilmington, MA, USA). All mice were housed for 1 week before any experiment in controlled conditions with 12-h light-dark cycles. EVs were isolated and purified by chromatography as previously described [37]. To investigate the protective effect of EVs and pFUS in cisplatin-induced AKI, animals were injected with cisplatin on day 0, administered pFUS on day 2, and treated with EVs on day 3 (Fig. 1b).

CD1 mice were randomly divided into 5 experimental groups, with each group containing 10 animals. Group 1 consisted of untreated control animals. For groups 2–5, animals received a single injection of cisplatin (12 mg/kg intraperitoneally) on day 0 to induce AKI. Group 2, AKI control, received no treatment; group 3, EVs alone, received EV treatment at a dose of 150 μg/100 g body weight via a tail vein injection on day 3; group 4, pFUS + EVs, received pFUS on day 2 followed by EVs on day 3; and group 5, pFUS alone, received pFUS only on day 2. At day 12 post-cisplatin injection, mice were sacrificed.
using an intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg) followed by cervical dislocation, at which point blood and kidney samples were collected. For blood samples, the blood was collected to obtain serum which was then stored at −20 °C for further analysis. One kidney was immediately immersed in 10% neutral buffered formalin for histological analysis while the other kidney was immediately frozen in liquid nitrogen for biochemical marker measurement and Western blot analysis. Subsequent analyses were conducted in a single-blind manner wherever possible.

**Pulsed focused ultrasound**

A 1.1-MHz central frequency custom high-intensity focused ultrasound (HIFU) therapy transducer (H-102NRE, Sonic Concepts, Bothell, WA, USA) with 49-mm central opening was used. The HIFU transducer was calibrated in a water tank filled with degassed and deionized water. The transducer was driven by an Agilent 33250A function generator (Agilent Technologies, Santa Clara, CA, USA) and connected to a 50-dB ENI 525LA linear power amplifier (ENI Technology, Inc., Rochester, NY, USA) and an impedance matching circuit (Sonic Concepts, Bothell, WA, USA). The transducer was excited at central 1.1-MHz frequency with 20 cycles at 100-Hz pulse repetition frequency (PRF) in a “burst” mode. A hydrophone (HNR-0500, Onda Corporation, Sunnyvale, CA, USA) was placed in the focal spot of the transducer (55 mm away from its surface) and an Acoustic Intensity Measurement System (AIMS III, Onda Corporation, Sunnyvale, CA, USA) was used for precise movement and positioning of the hydrophone and digitizing the waveforms. The measured beam profile (full width half-maximum area for pressure) at the focal area was 10 mm long and 1.5 mm in diameter. The intensity and pressure measurements were performed for negative peak pressures (NPP) up to 3 MPa in order to reduce risks related to hydrophone damage. The obtained intensities and NPP values were then scaled to the desired PRF and duty cycle (DC) and linearly extrapolated to higher pressures/intensities.

For image-guided therapy to the mouse kidneys, a setup of co-aligned transducers was employed. The imaging transducer (Siemens Acuson S2000 14 L5 sp., Siemens Corporation, WA, USA) was placed in the central opening of the HIFU transducer. Both transducers were then aligned and fixed in a custom-made 3D-printed holder. The HIFU transducer’s focal spot was fixed at 55 mm axial, 0 mm lateral distance from the central point of the imaging transducer. Any misalignment of the HIFU and imaging beam was checked several times in the water tank with the hydrophone and oscilloscope by assembling and disassembling the 3D-printed holder. On all measurements, the measured beam misalignment was less than 200 μm. The ultrasound guidance of the in vivo kidney therapy was done with the Siemens S2000 scanner (Siemens Medical Solutions, Issaquah, WA, USA). Mice were kept under isoflurane anesthesia (2.5% induction, 0.1% maintenance) and submerged vertically in the water tank with the head kept above the water surface and body temperature maintained at 37 °C. The assembled holder with the HIFU and imaging transducers was connected to a translation stage and kept in the water at approximately 50 mm axial distance from the mouse. The mouse’s kidney was identified on the Siemens S2000 scanner and placed at the desired location, 55 mm axially and 0 mm laterally from the central point of the imaging transducer. To treat the whole kidney, 8 non-overlapping adjacent regions through the kidney were targeted for 30 s per region. The time to treat one kidney with these parameters was approximately 4 min.

In order to deliver pFUS therapy to the animal, the HIFU transducer was used with the following parameters: 5% DC, 5 Hz PRF, 2.9 MPa PNP, and 272 W/cm² spatial average pulse average intensity (I_{SAPA}). After pFUS treatment, each mouse was removed from the water bath, dried, and placed in a recovery cage.

**Analysis of kidney function**

Blood samples were collected retro-orbitally from anesthetized mice for analysis of biochemical levels, including blood urea nitrogen (BUN) and creatinine (Cr) using reagents purchased from Santa Cruz biotechnology USA according to the manufacturer’s instructions mentioned in the ELISA kit. Serum neutrophil gelatinase-associated lipocalin (NGAL) was measured using a mouse NGAL Quantikine ELISA Kit (R&D Systems, USA) according to the manufacturer’s instructions. The ELISA kit for kidney injury molecule-1 (KIM-1) and TIMP metalloproteinase inhibitor 1 (TIMP-1) were purchased from Cell signaling USA, samples were analyzed according to the manufacturer’s instructions, and results were measured and calculated at 450 nm via an ELISA reader (Bio-Rad, CA, USA) within 10 min. Urine samples were collected from both the control and AKI groups and also evaluated for KIM-1, TIMP-1, NGAL, and creatinine. Renal tissues were also homogenized, and the supernatant removed after 15 min of centrifugation at 3000×g at 4 °C. Next, NGAL and KIM-1 levels were measured using commercial kits according to the manufacturer’s instructions (R&D Systems, USA).

**Histology, immunohistochemistry, and immunofluorescence**

At day 12, the mice were sacrificed and then perfused with 4% (vol/vol) paraformaldehyde in PBS to remove the blood from the tissues. Next, whole kidney tissues were fixed for 24 h in 4% (vol/vol) paraformaldehyde.
After fixation and paraffin embedding, the kidney tissues were then sectioned into 6-μm slices for hematoxylin–eosin and trichrome staining. The slides were also stained with 4’,6-diamidino-2-phenylindole (DAPI) (D1306, Thermo Fisher Scientific, Santa Clara, CA, USA) and processed for GFP signal quantification using ImageJ software (NIH, USA) and flow cytometry as described previously [38].

Pathological score for tubular injury

To determine kidney injury and rescue at the tissue level, we used a semi-quantitative histological scoring method previously defined by Klopfeisch et al. [39]. Injury was defined by dilated tubules, glomerular casts, tubular casts, necrosis, and tubular degeneration. The number of casts and tubular profiles showing necrosis were recorded in a single-blind fashion. Score 0 represents injury area less than 10%, whereas scores 1, 2, 3, and 4 represent injury involving 10–25%, 25–50%, 50–75%, or > 75% of the visualized field, respectively. At least 20 random fields at ×200 magnification were evaluated for each mouse with the average score calculated.

Real-time PCR

RNA was extracted from kidney homogenized tissue using a Trizol Reagent (Sigma-Aldrich MO, USA). After digestion with DNase I, 2 μg RNA was reverse transcribed with the Applied Biosystems reverse transcriptase kit (Applied Biosystems, CA, USA). The quality of cDNA was assessed by the ratio of the absorbance at 260 nm and 280 nm using an Agilent 2100 Bioanalyzer (Agilent Bioanalyser, CA, USA). cDNA was then amplified by PCR in an iCycler Thermal Cycler (Bio-Rad, CA, USA) with SYBR Green (Applied Biosystems, CA, USA) and specific primers for Kim1 (Mm01291075_m1, Thermo Fisher Scientific, Santa Clara, CA, USA), Timp1 (Mm01341361_m1, Thermo Fisher Scientific, Santa Clara, CA, USA), Ngal (Mm00443258_m1, Thermo Fisher Scientific, Santa Clara, CA, USA), Il6 (Mm00446190_m1, Thermo Fisher Scientific, Santa Clara, CA, USA), Tfna (Mm00443258_m1, Thermo Fisher Scientific, Santa Clara, CA, USA), Gapdh (Mm99999915_g1, Thermo Fisher Scientific, Santa Clara, CA, USA), and 18S (Mm02601777_g1, Thermo Fisher Scientific, Santa Clara, CA, USA); the latter two were used as housekeeping genes. The expression of marker genes was normalized to the endogenous

Western blot analysis

Kidney tissue was sliced into thin sections, followed by sonication and homogenization. The lysate was then placed in 1× SDS sample buffer in association with radioimmunoprecipitation assay (RIPA) buffer solution containing 1% NP40, 0.1% SDS, 100 mg/ml PMSF, 1% protease inhibitor cocktail, and 1% phosphatase I and II inhibitor cocktail (Sigma, St Louis, MO, USA) on ice. The supernatant was then collected following centrifugation at 13,000g at 4°C for 30 min. Protein concentration was determined by a bichinchoninic acid protein assay. An equal amount of protein was loaded into 10% or 15% SDS-PAGE and transferred onto polyvinylidene difluoride membranes. The primary antibodies were used at 1:200 dilution unless otherwise noted: Akt (2920S, Cell Signaling Technology, MA, USA), p-Akt (PA5-95669, Thermo Fisher Scientific, Santa Clara, CA, USA), KIM-1 (PA5-98302, Thermo Fisher Scientific, Santa Clara, CA, USA), NGAL (ABS 043-29-02, Thermo Fisher Scientific, Santa Clara, CA, USA), TIMP-1 (MA5-13688, Thermo Fisher Scientific, Santa Clara, CA, USA), TNF-α (MM350C, Thermo Fisher Scientific, Santa Clara, CA, USA), NF-κB (PA5-16545, Thermo Fisher Scientific, Santa Clara, CA, USA), endothelial nitric oxide synthase (eNOS) (5880S, Cell Signaling Technology, MA, USA), SIRT3 (8469S, Cell Signaling Technology, MA, USA), PCNA (13-3900, Thermo Fisher Scientific, Santa Clara, CA, USA), VEGF (MA5-13182, Thermo Fisher Scientific, Santa Clara, CA, USA), survivin (PA1-16836, Thermo Fisher Scientific, Santa Clara, CA, USA), Bcl-2 (MA5-11757, Thermo Fisher Scientific, Santa Clara, CA, USA), BAX (MA5-14003, Thermo Fisher Scientific, Santa Clara, CA, USA), Caspase-3 (MA5-11521, Thermo Fisher Scientific, Santa Clara, CA, USA), p-ERK (MA5-15705, Thermo Fisher Scientific, Santa Clara, CA, USA), ERK (13-8600, Thermo Fisher Scientific, Santa Clara, CA, USA), p-MEK (sc-271914, Santa Cruz Biotechnology, TX, USA), MEK (sc6250, Santa Cruz Biotechnology, TX, USA), and anti-β-actin (sc-1616, 1:1000 dilution, Santa Cruz Biotechnology, TX, USA). Quantification was performed by measuring the intensity of the signals with the aid of the National Institutes of Health Image software package and Bio-Rad image software (Bio-Rad USA).
*Gapdh* expression level and calculated with the $2^{-\Delta\Delta Ct}$ formula in % *Gapdh* expression [40].

**Statistical analysis**
All data are expressed as the mean ± standard deviation (SD) and analyzed with analysis of variance (ANOVA) followed by the Tukey test. Statistical analysis was performed using the GraphPad Prism 8.0 software (Graphpad Software, Inc., San Diego, USA).

**Results**

**EVs and pFUS reduce the clinical manifestations of AKI**
EVs were confirmed to be positive for the expression of CD9, CD63, and TSG101, with quantification normalized to the internal control CD81 (CD9: 5.77 ± 1.34 relative expression; CD63: 2.25 ± 1.66 relative expression; TSG101: 8.64 ± 6.10 relative expression) (Fig. 1a). Cisplatin was administered to induce AKI on day 0, after which animals were treated with pFUS on day 2 or EVs on day 3 (Fig. 1b). There was a reduction in the survival of animals in the AKI (80%) and pFUS alone (90%) groups at day 12, compared to untreated controls (100%) (Fig. 1c). However, animals treated with EVs alone or pFUS + EVs showed no mortality at day 12. A similar trend was observed in kidney weight following cisplatin administration: compared to untreated controls, kidney weight was significantly reduced among animals in the AKI (0.17 ± 0.04 vs. 0.23 ± 0.01 g, p < 0.05) and pFUS alone groups (0.17 ± 0.02 vs. 0.23 ± 0.01 g, p < 0.05). Compared to the AKI group, treatment with EVs alone partially ameliorated this reduction in kidney weight (0.19 ± 0.03 vs. 0.17 ± 0.04 g, p > 0.05) (Fig. 1c). These trends were also reflected in serum laboratory values. At day 12, animals in the AKI group showed significantly elevated levels of several kidney injury markers compared to untreated controls, including blood urea nitrogen (BUN) (13.27 ± 1.26 vs. 150.23 ± 9.62 mg/dL, p < 0.05), creatinine (Scr) (0.31 ± 0.01 vs. 1.83 ± 0.08 mg/dL, p < 0.05), and NGAL (1.25 ± 0.19 vs. 4.54 ± 0.68 mg/mL, p < 0.05) (Fig. 1d). Compared to AKI, treatment with EVs alone significantly reduced the levels of all three injury markers (BUN: 150.23 ± 9.26 vs. 72.23 ± 5.61 mg/dL, p < 0.05; Scr: 1.83 ± 0.08 vs. 0.99 ± 0.01 mg/dL, p < 0.05; NGAL: 4.53 ± 0.68 vs. 2.11 ± 0.33 mg/mL, p < 0.05), and the combined treatment of pFUS + EVs further reduced all these markers compared to treatment with EVs alone (BUN: 50.74 ± 3.34 vs. 72.23 ± 5.61 mg/dL, p < 0.05; Scr: 0.61 ± 0.02 vs. 0.99 ± 0.01 mg/dL, p < 0.05; NGAL: 1.70 ± 0.42 vs. 2.11 ± 0.33 mg/mL, p > 0.05).

**EV homing to the kidney is not enhanced following pFUS**
Following the development of AKI in mice, IV-administered EVs were able to home to the injured kidney, as demonstrated by the detection of GFP-labeled EVs within the kidney tissue at day 12 (Fig. 2a). However, pFUS had no additional effect on EV homing, as demonstrated by both histological detection and flow cytometry analysis (0.05 ± 0.02% vs. 0.05 ± 0.03% GFP positive, p > 0.05). As expected, no expression of GFP was detected in the kidneys of animals not treated with EVs.

**EVs and pFUS reverse histological and molecular markers of kidney damage**
Histological evaluation of kidney tissue demonstrated that cisplatin induced a significant increase in injury compared to untreated controls, as demonstrated by the presence of morphological changes within the kidney parenchyma, including glomerular casts, tubular casts, and fibrosis (Fig. 2b). This injury was reflected in a higher histological injury score in the AKI group compared to untreated controls (3.65 ± 1.81 vs. 0.43 ± 0.16, p < 0.05). Compared to the AKI group, those treated with EVs alone showed a dramatically lower injury score (3.65 ± 1.81 vs. 1.90 ± 0.31, p < 0.05), pFUS alone also resulted in a lower injury score (3.65 ± 1.81 vs. 2.57 ± 0.66, p > 0.05) that did not reach statistical significance. Animals in the combined pFUS + EVs group had further reduced injury scores compared to those receiving either EVs alone (1.40 ± 0.45 vs. 1.90 ± 0.31, p > 0.05) or pFUS alone (1.40 ± 0.45 vs. 2.57 ± 0.66, p > 0.05), though these differences did not reach statistical significance (Fig. 2b).

These trends were further confirmed by measuring the levels of tissue damage markers KIM-1 and TIMP-1. Immunohistochemical (IHC) staining of kidney tissue showed that untreated controls do not express these two molecules, but cisplatin-induced AKI strongly upregulated both markers (Fig. 3a). Although pFUS alone was not able to reduce their expression, EVs alone were able to partially reduce these two markers. Moreover, the combination of pFUS + EV treatment almost completely eliminated their presence (Fig. 3a). Western blot analysis further confirmed these trends: compared to the AKI group, EVs alone were able to partially reduce levels of KIM-1 (0.55 ± 0.16 vs. 0.38 ± 0.17 normalized expression, p > 0.05) and TIMP-1 (0.64 ± 0.40 vs. 0.38 ± 0.08 normalized expression, p > 0.05), but combined EVs + pFUS treatment showed much greater reductions in KIM-1 (0.55 ± 0.16 vs. 0.12 ± 0.02 normalized expression, p < 0.05), NGAL (0.44 ± 0.23 vs. 0.08 ± 0.02 normalized expression, p < 0.05), and TIMP-1 (0.64 ± 0.40 vs. 0.19 ± 0.11 normalized expression, p > 0.05) (Fig. 3b). qRT-PCR analysis on mRNA expression in kidney tissue (Fig. 3c), as well as ELISA analysis on urine samples, further recapitulated these trends (Fig. 3d).

**EVs and pFUS reduce inflammatory cytokines in the setting of AKI**
Having established the regenerative capabilities of EVs, we next sought to elucidate the biological mechanisms...
through which they reverse AKI-induced kidney damage. We found by IHC that cisplatin-induced AKI is characterized by high levels of inflammatory markers in the kidney, including TNF-α and IL-6 (Fig. 4a). Treatment with either EVs, pFUS, or the combined treatment dramatically reduced the expression of these cytokines. Western blot analysis further supported these trends. Combined pFUS + EV treatment reduced TNF-α more so than EVs alone (0.34 ± 0.02 vs. 0.47 ± 0.07 normalized expression, p > 0.05), as was the case with its downstream signaling protein NF-kB (0.20 ± 0.08 vs. 0.65 ± 0.31 normalized expression, p > 0.05), though these results did not reach statistical significance (Fig. 4b). Similar trends were observed with qRT-PCR analysis of kidney tissue mRNA: compared to untreated controls, cisplatin-induced AKI resulted in elevated transcript levels of *Nfkb* (78.88 ± 9.85 vs. 178.76 ± 41.93 relative expression, p < 0.05), *Il6* (88.08 ± 1.65 vs. 144.56 ± 30.67 relative expression, p > 0.05), and *Tnfa* (87.07 ± 9.06 vs. 108.95 ± 14.96 relative expression, p < 0.05) (Fig. 4c). Treatment with EVs, with or without pFUS, was able to bring transcript levels of these cytokines back to levels comparable to those of untreated controls. ELISA analysis also showed a significant reduction in serum cytokine levels when comparing the AKI group with those treated with pFUS + EVs, including TNF-α (1187 ± 142 vs. 463 ± 65 pg/mL, p < 0.05), IL-6 (1087 ± 90 vs. 290 ± 47 pg/mL, p < 0.05), and IL-1β (547 ± 75 vs. 290 ± 47 pg/mL, p < 0.05) (Fig. 4d). In fact, animals treated with the combined pFUS + EVs showed significantly more potent reduction in IL-6 and TNF-α compared to those treated with EVs alone (IL-6 454 ± 78 vs. 769 ± 109 pg/mL, p < 0.05; TNF-α 463 ± 65 vs. 987 ± 143 pg/mL, p < 0.05; IL-1β 290 ± 47 vs. 135 ± 33 pg/mL, p < 0.05).
Fig. 3 Molecular markers of kidney injury. a Immunohistochemical staining showing expression of injury markers KIM-1 and TIMP-1. Scale bar represents 100 μm. b Western blot for KIM-1, NGAL, TIMP-1, and β-actin (left), and their respective quantification (right). c Quantitative real-time PCR for Kim1, Ngal, and Timp1 in the kidney tissue. d ELISA for KIM-1, NGAL, and TIMP-1 measured in the urine. Each group has n = 5 mice. Significant difference *p < 0.05: relative to untreated control; †p < 0.05: relative to AKI; ‡p < 0.05: relative to AKI-EV; ‡‡p < 0.05: relative to AKI-EV-pFUS.
EVs and pFUS promote proliferation and inhibit apoptosis

Modulation of cell proliferation and apoptosis may be another mechanism by which EVs may exert their therapeutic effect. Using IHC staining, we found that compared to untreated controls, the AKI group had dramatically reduced cell proliferation in the kidney, as measured by the proliferation marker Ki67 (6.21 ± 2.26% vs. 2.01 ± 1.21% Ki67\(^+\), \(p < 0.05\)) (Fig. 5a). Compared to the AKI group, the percentage of proliferating cells was restored after treatment with EVs alone (9.7 ± 3.35% vs. 2.01 ± 1.21% Ki67\(^+\), \(p < 0.05\)) or pFUS alone (8.77 ± 2.45% vs. 2.01 ± 1.21% Ki67\(^+\), \(p < 0.05\)), and the combined pFUS + EV treatment showed the greatest effect (14.67 ± 3.20% vs. 2.01 ± 1.21% Ki67\(^+\), \(p < 0.05\)), significantly more than either treatment alone. We also measured the expression of several proliferation markers by Western blot, including PCNA, VEGF, and survivin. EVs alone were able to somewhat increase PCNA, VEGF, and survivin expression compared to the AKI group, though the difference did not reach statistical significance. pFUS alone was only able to increase PCNA levels. Compared to the AKI group, the combination of pFUS + EVs was able to increase the levels of PCNA (1.68 ± 0.30 vs. 3.80 ± 0.47 normalized expression, \(p < 0.05\)), VEGF (1.02 ± 0.46 vs. 1.85 ± 0.25 normalized expression, \(p > 0.05\)), and survivin (0.23 ± 0.04 vs. 1.16 ± 0.97 normalized expression, \(p > 0.05\)), more so than either treatment alone (Fig. 5b).

In addition to proliferation, we also measured apoptosis markers (BAX, Bcl-2, Caspase-3) in the kidney tissue. IHC analysis showed that AKI strongly upregulated Caspase-3, indicative of significant apoptosis following injury (Fig. 5c). Both EVs alone and pFUS alone reduced the amount of Caspase-3, but the combined treatment of pFUS + EVs showed an even greater reduction. Western blot analysis further showed that EVs alone strongly upregulated the expression of anti-apoptotic proteins like Bcl-2 compared to the AKI group (1.18 ± 0.02 vs. 0.47 ± 0.11 normalized expression, \(p < 0.05\)) and that the combination of pFUS + EVs resulted in an even greater increase compared to EVs alone (1.88 ± 0.27 vs. 1.18 ± 0.02 normalized expression, \(p > 0.05\)) (Fig. 5d). On the other hand, compared to the AKI group, pro-apoptotic genes like BAX and Caspase-3 were downregulated by both EVs alone (BAX 0.10 ± 0.01 vs. 0.15 ± 0.06 normalized expression, \(p < 0.05\); Caspase-3 1.63 ± 0.24 vs. 2.99 ± 0.95 normalized expression, \(p > 0.05\)) and by pFUS alone (BAX 0.07 ± 0.01 vs. 0.15 ± 0.06 normalized expression, \(p > 0.05\); Caspase-3 1.29 ± 0.53 vs. 2.99 ± 0.94 normalized expression, \(p > 0.05\)).

Discussion

In this study, we demonstrated that EVs are capable of reversing cisplatin-induced AKI and that this regenerative
effect is enhanced when they are used in combination with pFUS. We have demonstrated several mechanisms by which EVs and pFUS exert a synergistic therapeutic effect, including (1) a reduction in inflammatory cytokines, (2) an increase in cell proliferation, and (3) a decrease in apoptosis. These effects are mediated by increased MAPK/ERK and PI3K/Akt signaling and upregulation of the SIRT3 and eNOS pathways.

pFUS presents a promising method for optimizing MSC-based therapies [28]. It is a non-invasive procedure that can be precisely targeted to deep structures in the body and has an excellent safety profile [32, 34]; indeed, focused ultrasound is already FDA-approved for various clinical applications [41]. Burks et al. have previously tested pFUS in the setting of cisplatin-induced AKI, though there are some discrepancies between their studies and ours [30]. In AKI, they found that pFUS alone did not significantly improve kidney function (creatinine and BUN), promote cell proliferation (Ki67 and p-Akt), or reduce apoptosis and necrosis. However, pFUS alone did elicit these effects in our current and previous experiments [29, 42]. This discrepancy may result from different ultrasound transducers and settings; given that there is a lack of data on how the biological effects of pFUS are influenced by specific ultrasound parameters, direct comparison between studies is difficult.
These discrepancies suggest that there are different molecular mechanisms by which pFUS operates, depending on ultrasound parameters. The studies by Burks et al. show that pFUS transiently activates TNF-α and IL-1α expression in the sonicated tissue, which act through NF-κB signaling to drive cyclooxygenase-2 (COX2) activity; in turn, this promotes the expression of several homing factors and increases the local accumulation of MSCs, thus augmenting their therapeutic effect [43, 44]. Our previous studies have shown, however, that pFUS can improve MSC therapy independently of improved homing [29]. Instead, pFUS modulates the expression of heat shock proteins (HSPs), leading to various downstream effects such as increased proliferation through PI3K/Akt signaling [29] and suppression of inflammation [42]. In line with these previously reported mechanisms, the current study has identified the involvement of MAPK/ERK and PI3K/Akt signaling, canonical pathways for cell proliferation and survival that play a role in facilitating regeneration of damaged tissue [45, 46]. Our study also implicates the SIRT3 and eNOS pathways. SIRT3 is a mitochondrial protein deacetylase known for its ability to regulate energy demand during stressful conditions, eliminate reactive oxygen species, and prevent apoptosis [47]. eNOS, the endothelial nitric oxide synthase, has been shown to play an important role in neovascularization [48]. The involvement of these two pathways further suggests that EVs and pFUS can induce angiogenesis and stimulate regeneration.

One notable result of our study is that pFUS did not increase EV homing to the kidney. Homing is not a passive process, but an active one that requires a sequential series of molecular interactions. The homing process for MSCs is well-characterized: in order to travel from circulation into a target tissue, they must undergo (1) tethering by selectins, (2) activation by chemokines, (3) arrest by integrins, (4) transmigration or diapedesis across the endothelial layer, and (5) extravascular migration to the target tissue mediated by cytokines [49]. pFUS at certain parameters can enhance this process by upregulating homing molecules at the target tissue, especially chemokines like SDF-1 and cell adhesion molecules like VCAM-1 [31–34]. Many studies have demonstrated increased MSC homing following pFUS
sound parameters. It is also possible that there may be others [30], which may be an effect of different ultrasound can prevent AKI by stimulating cholinergic anti-inflammatory cytokines, induce PI3K/Akt signaling with subsequent increases in proliferating cells and decreased apoptosis, and upregulate SIRT3 and eNOS. Consistent with these findings, a previous study has shown that ultrasound can prevent AKI by stimulating cholinergic anti-inflammatory pathways [58], though that study used unfocused ultrasound. These effects of pFUS alone were observed in some previous studies [29, 42], but not others [30], which may be an effect of different ultrasound parameters. It is also possible that there may be

Conclusions

Our study demonstrates that the combination of pFUS + EVs is therapeutic in the setting of cisplatin-induced AKI, superior to either EVs or pFUS alone. AKI represents a growing clinical concern for which there are no curative therapies. Though there has been considerable preclinical success in using EVs therapeutically, more optimization remains to be done before they may reach clinical utility. EVs are an attractive cell-free alternative to MSC therapy. Their small size bypasses the pulmonary first-pass effect, where the vast majority of IV-infused MSCs become entrapped in the lung microvasculature [19–23]. EVs also obviate the need for a constant supply of cells and avoid concerns regarding unwanted engraftment or immune rejection [59]. Rigorous molecular characterization of the mechanisms underlying EV and pFUS therapy, alongside a better understanding of pFUS parameters, will be key to fully realizing their clinical potential.

Abbreviations

AKI: Acute kidney injury; BM: Bone marrow; BUN: Blood urea nitrogen; CKD: Chronic kidney disease; Cr: Creatinine; DAPI: 4′,6-Diamidino-2-phenylindole; DMEM: Dulbecco’s modified Eagle medium; eNOS: Endothelial nitric oxide synthase; ERK: Extracellular signal-regulated kinase; ESRD: End-stage renal disease; EV: Extracellular vesicle; GFP: Green fluorescent protein; HIFU: High-intensity focused ultrasound; IHC: Immunohistochemistry; IL: Interleukin; ICAM: Intercellular adhesion molecule; IFN: Interferon; NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells; NGAL: Neutrophil gelatinase-associated lipocalin; NTA: Nanoparticle tracking analysis; PBS: Phosphate-buffered saline; PCNA: Proliferating cell nuclear antigen; pFUS: Pulsed focused ultrasound; PI3K: Phosphoinositide 3-kinase; RIPA: Radioimmunoprecipitation assay; SDF-1: Stromal cell-derived factor 1; SDS: Sodium dodecyl sulfate; SIRT3: Sirtuin 3; TIMP-1: TIMP metallopeptidase inhibitor 1; TNF-α: Tumor necrosis factor alpha; VEGF: Vascular endothelial growth factor

Acknowledgements

Not applicable.

Authors’ contributions

Conceptualization, M.U., W.C., and A.S.T.; methodology, M.U. and A.S.T.; investigation, M.U., D.D.L., S.R., and M.R.; writing, M.U., D.D.L., and A.S.T.; funding acquisition, W.C. and A.S.T.; supervision, W.C. and A.S.T. The authors read and approved the final manuscript.

Funding

The authors would like to acknowledge support from “The Kidney For Dane Community,” the Akiko Yamazaki and Jerry Yang Faculty Scholar Fund in Pediatric Translational Medicine, and the Stanford Maternal and Child Health Research Institute.

Availability of data and materials

The data that support the findings of this study are available from the corresponding author upon reasonable request.
Ethics approval and consent to participate
All experimental procedures involving animals were performed in accordance with the guidelines and regulations of the Administrative Panel on Laboratory Animal Care (APLAC) at Stanford University.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 2 July 2020 Revised: 24 August 2020
Accepted: 2 September 2020 Published online: 14 September 2020

References
1. Levey AS, James MT. Acute kidney injury. Ann Intern Med. 2017;167(9):ITC66–80.
2. Pavkov ME, Harding JL, Burrows NR. Trends in hospitalizations for acute kidney injury - United States, 2000-2014. MMWR Mortal Mortal Wkly Rep. 2018;67(10):899–93.
3. Kello NM, et al. National trends in acute kidney injury requiring dialysis in England between 1998 and 2013. Kidney Int. 2015;88(5):161–9.
4. Carlson N, et al. Trends in one-year outcomes of dialysis-requiring acute kidney injury in Denmark 2005-2012: a population-based nationwide study. PLoS One. 2016;11(7)e0159944.
5. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease: promises and challenges. J Cell Mol Med. 2018;22(2):728–37.
6. Phinney DG, Pettenger MF. Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells. 2017;35(4):851–8.
7. Cheng L, et al. Focus on mesenchymal stem cell-derived exosomes: opportunities and challenges in cell-free therapy. Stem Cells Int. 2017;2017(2030295).
8. Ullah M, et al. A novel approach to deliver therapeutic extracellular vesicles directly into the mouse kidney via its arterial blood supply. Cells. 2020;9(4):937.
9. Liu DD, et al. The role of ultrasound in enhancing mesenchymal stromal cell-based therapies. Stem Cells Transl Med. 2020;9(8):850–66.
10. Ullah M, et al. Reversing acute kidney injury using pulsed focused ultrasound and MSC therapy: a role for HSP-mediated PI3K/AKT signaling. Mol Ther Methods Clin Dev. 2020;7:688–94.
11. Burks SR, et al. Pulsed focused ultrasound pretreatment improves mesenchymal stromal cell efficacy in preventing and rescuing established acute kidney injury in mice. Stem Cells. 2015;33(4):1241–53.
12. Tebebi PA, et al. Improving the therapeutic efficacy of mesenchymal stromal cells to restore perfusion in critical limb ischemia through pulsed focused ultrasound. Sci Rep. 2017;7:14550.
13. Burks SR, et al. Mesenchymal stromal cell potency to treat acute kidney injury increased by ultrasound-activated interferon-gamma/interleukin-10 axis. J Cell Mol Med. 2018;22(2):6015–25.
14. Kim DK, et al. Chromatographically isolated CD63+CD81+ extracellular vesicles from mesenchymal stromal cells rescue cognitive impairments after TBI. Proc Natl Acad Sci U S A. 2016;113(11):170–5.
15. Bartosh TJ, et al. Cancer cells enter dormancy after cannibalizing mesenchymal stem/stromal cells (MSCs). Proc Natl Acad Sci U S A. 2016;113(2):1647–56.
16. Kopfleisch R. Multiparametric and semiquantitative scoring systems for the evaluation of mouse model histopathology-a systematic review. BMC Vet Res. 2013;129.
17. Pannu N. Bidirectional relationships between acute kidney injury and chronic kidney disease: promises and challenges. J Cell Mol Med. 2018;22(12):6015–27.
18. Morild I, et al. Adrenal androgen receptors mediate endothelial cell responses to menstruation. J Cell Physiol. 2014;229(8):1349–62.
19. Tempany CM, et al. Focused ultrasound surgery in oncology: overview and principles. Radiology. 2011;259(1):39–50.
20. Anderson JD, et al. Comprehensive proteomic analysis of mesenchymal stromal cells by noninvasive pulsed focused ultrasound. Stem Cells. 2017;35(6):1216–27.
21. Phinney DG, Pettenger MF. Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells. 2017;35(4):851–8.
22. Schrepfer S, et al. Stem cell transplantation: the lung barrier. Transplant Proc. 2009;41(3):915–8.
23. Feichtinger R. Biodistribution, migration and homing of systemically applied mesenchymal stem/stromal cells. Stem Cell Res Ther. 2016;77.
24. Eggenhofer E, et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol. 2012;297.
25. Fischer UM, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 2009;18(5):683–92.
26. Lv LL, et al. Therapeutic application of extracellular vesicles in kidney disease: promises and challenges. J Cell Mol Med. 2018;22(2):728–37.
53. Bruno S, et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol. 2009;20(5):1053–67.
54. Sackstein R, et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med. 2008;14(2):181–7.
55. Shimaoka M, et al. Connexins and integrins in exosomes. Cancers (Basel). 2019;11(1):106.
56. Bai L, et al. Ultrasound facilitates naturally equipped exosomes derived from macrophages and blood serum for orthotopic glioma treatment. ACS Appl Mater Interfaces. 2019;11(16):14576–87.
57. Kovacs ZI, et al. Disrupting the blood-brain barrier by focused ultrasound induces sterile inflammation. Proc Natl Acad Sci U S A. 2017;114(1):E75–84.
58. Gigliotti JC, et al. Ultrasound prevents renal ischemia-reperfusion injury by stimulating the splenic cholinergic anti-inflammatory pathway. J Am Soc Nephrol. 2013;24(9):1451–60.
59. Lou C, et al. Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases. Exp Mol Med. 2017;49(9):e346.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.